Find
Home
Clinical Trials
Symptom Management
Videos
OncUTube Home
Continuing Education
Calendar
Links
You are here:
Videos
Register
|
Login
Install latest flash player if this video gallery doesn't work.
SHARE THIS VIDEO
Management Considerations for Patients with Myeloproliferative Neoplasms
A discussion with a panel of global key thought leaders regarding Myeloproliferative Neoplasms (MPNs). To learn more about MPNs please visit Exploring MPN at www.exploringmpn.com.
ExploringMPN Website
Recent Video
| 
Most Viewed
Tumor Type :
<All Tumor Types>
Advocacy Group Interviews
Brain Cancer
Breast Cancer
Clinical Trial Cooperative Groups
Colorectal Cancer
Gastric Cancer
Gastrointestinal Stromal Tumor (GIST) Cancer
General Educational Topics
Head and Neck Cancer
Headline News
Leukemia
Lung Cancer
Lymphoma
Melanoma
Myeloma
Myeloproliferative Neoplasms (MPN)
Neuroendocrine Tumors (NET)
Oncology Nursing Society
Ovarian Cancer
Pancreatic Cancer
Pediatric Oncology
Prostate Cancer
Renal Cell Carcinoma (Kidney) Cancer
Sarcomas
Supportive Care
Symptom Management
Technology and Medicine
Thyroid Cancer
Search :
Update on JAK Inhibitor — COMFORT II Trial i...
06:50
Update on JAK Inhibitor — Spleen Volume Redu...
10:20
Overview of the COMFORT II trial and discuss...
07:58
COMFORT II Discussion with Dr. Claire Harris...
05:45
COMFORT II - Why is spleen volume so importa...
05:29
COMFORT II Additional Data Discussion with D...
01:35
What do the results of the COMFORT I and II ...
02:43
JAK Inhibitor Ruxolitinib COMFORT-II Trial S...
06:19
An Overview of Myelofibrosis
04:42
What Do Patients with Myelofibrosis Need to ...
04:21
JAK/STAT Pathway: Discussion on Current Stud...
00:36
JAK/STAT Pathway: Overview
02:32
Management Considerations for Patients with ...
01:49
Myeloproliferative Neoplasms: Clinical Prese...
03:08
Myeloproliferative Neoplasms: WHO Classifica...
01:33
What Are Myeloproliferative Neoplasms (MPNs)...
02:53
RSS this page
Advertise on OncUView.tv
Privacy Statement
|
Terms Of Use
|
Copyright 2010-2011 by OncUView.tv, LLC